Search results
Results from the WOW.Com Content Network
In 2008, the US Food and Drug Administration (FDA) issued a communication warning of the possibility of severe and sometimes incapacitating bone, joint or muscle pain. [8] A study conducted by the American Society of Bone and Mineral Research concluded that long-term use of bisphosphonates, including Boniva, may increase the risk of a rare but serious fracture of the femur. [9]
Boniva may refer to: Boniva, a company acquired by software company SSA Global Technologies in August 2005 Ibandronic acid (marketed as Boniva), a potent bisphosphonate drug used in the prevention and treatment of osteoporosis
The manufacturers of Boniva, a rival bisphosphonate, were accused in the suit of causing a "serious public health risk" through misrepresentation of scientific findings. In a ruling on September 7, 2006, U.S. District Judge Paul A. Crotty rejected P&G's attempted injunction. P&G was criticized for attempting to "preserve its market share by ...
The general chemical structure of bisphosphonate. The R-groups determine the chemical properties of the drug, and distinguishes individual types of bisphosphonates. This chemical structure affords a high affinity for calcium hydroxyapatite, allowing for rapid and specific skeletal targeting.
Ambirix (for hepatitis A (inactivated) and hepatitis B (rDNA) (HAB) vaccine (adsorbed)); Arexvy (for RSV); Bexsero (for meningitis B); Boostrix (for tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine, adsorbed)
Global headquarters, Research Triangle Park, North Carolina. Stiefel Laboratories Inc. is an American dermatological pharmaceutical company, with its global headquarters in Research Triangle Park, North Carolina. [1]
First released in 1999, annual sales peaked at approximately $2.5-billion in 2006; however, following a meta-analysis in 2007 that linked the drug's use to an increased risk of heart attack, [1] sales plummeted to just $9.5-million in 2012. The drug's patent expired in 2012. [2] It was patented in 1987 and approved for medical use in 1999. [3]
Current recommendations are for a 2-month drug holiday prior to dental surgery for those who are at risk (intravenous drug therapy, greater than 4 years of by-mouth drug therapy, other factors that increase risk such as steroid therapy). [7] It usually develops after dental treatments involving exposure of bone or trauma, but may arise ...